The Claim
Higher baseline levels of growth differentiation factor 15 (GDF15) and osteopontin (OPN) are associated with greater declines in physical function, as measured by the Short Physical Performance Battery (SPPB), over a 6-month period in older adults with mobility limitations.
What the research says
Supports is higher
Support is ahead, but a single strong opposing study can change this.
These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.
Older adults with mobility limitations who start with higher levels of GDF15 and osteopontin in their blood experience greater reductions in physical function over six months, as measured by standard mobility tests.
See the scientific wording
Higher baseline levels of growth differentiation factor 15 (GDF15) and osteopontin (OPN) are associated with greater declines in physical function, measured by the Short Physical Performance Battery (SPPB), over 6 months in older adults with mobility limitations, independent of intervention group.
Older adults with more damaged, non-dividing cells in their tissues release chemicals that cause chronic inflammation and break down muscle, leading to weaker muscles, poorer balance, and slower walking speed.
What the research says
1 studyOlder adults with more of these two blood chemicals (GDF15 and osteopontin) at the start tended to get weaker at walking and balancing over time, no matter if they exercised or just got health advice. The study found this link.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.